

---

*primary studies - published, non RCT*

## **Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor.**

**Code:** PM28143919

**Year:** 2017 **Date:** 2017

**Author:** Stalvey MS

### **Study design (if review, criteria of inclusion for studies)**

Post hoc analysis (2 clinical trials, the longitudinal-observation GOAL study and the placebo-controlled ENVISION study)

### **Participants**

83 children (aged 6-11 years) enrolled in 2 clinical trials, the longitudinal-observation GOAL study and the placebo-controlled ENVISION study

### **Interventions**

Ivacaftor

### **Outcome measures**

Height and weight z scores and height and weight growth velocities (GVs).

### **Main results**

In ivacaftor-treated children in GOAL, height and weight z scores increased significantly from baseline to 6 months (increases of 0.1 [P

### **Authors' conclusions**

Ivacaftor treatment in prepubescent children may help to address short stature and altered GV in children with CF; results from these analyses support the existence of an intrinsic defect in the growth of children with CF that may be ameliorated by CFTR modulation.

<http://dx.doi.org/10.1542/peds.2016-2522>

### **See also**

Pediatrics. 2017 Feb;139(2). pii: e20162522. doi: 10.1542/peds.2016-2522.

### **Keywords**

Child; Hormones; pharmacological\_intervention; Recombinant Proteins; Growth Hormone;